Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$5m takes prostate disorder co closer to market

This article was originally published in Clinica

Executive Summary

MD Venture Partners, an Irvine, California-based healthcare VC, has invested $5m in ProstimRx, a company developing a medical device for treating prostate-related disorders. Hendersonville, Tennessee-based ProstimRx said it intends to use the funds to gain US FDA clearance and CE-marking for its technology. The ProstimRx procedure has been used in over 10,000 clinical cases to treat prostatitis, benign prostate hypertrophy, erectile dysfunction and other diseases linked to the prostate problems.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel